logo
    Artbio

    At a Glance

    Healthcare / Healthtech

    11-50

    Overview

    Artbio is a clinical-stage radiopharmaceutical company dedicated to transforming cancer care through the development of alpha radioligand therapies. Utilizing its proprietary AlphaDirect technology for the efficient isolation and production of the isotope 212Pb, Artbio crafts therapeutics that selectively target tumors with a focus on maximizing efficacy and safety. With a rich scientific heritage stemming from nearly a century of research at the University of Oslo’s Norways Radium Hospital, Artbio is advancing several pipeline programs, including a lead initiative currently in first-in-human trials. The company operates globally, with a presence in cities like Boston, Basel, London, and Oslo, fostering a collaborative and innovative culture aimed at reducing the burden of cancer treatment while elevating clinical outcomes for patients. Artbio is committed to diversity, equity, and inclusion, creating an environment where all employees can thrive and contribute to the mission of improving cancer care.

    Actions